Section Arrow
CHRS.NASDAQ
- Coherus Oncology Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/07/20 13:17 EDT
Regular Hours
Last
 0.8808
-0.015 (-1.67%)
Day High 
0.9299 
Prev. Close
0.8958 
1-M High
0.96 
Volume 
606.53K 
Bid
0.88
Ask
0.9189
Day Low
0.8748 
Open
0.92 
1-M Low
0.71 
Market Cap 
103.85M 
Currency USD 
P/E 2.04 
%Yield -- 
10-SMA 0.86 
20-SMA 0.8 
50-SMA 0.81 
52-W High 2.43 
52-W Low 0.6603 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.15/-0.60
Enterprise Value
372.07M
Balance Sheet
Book Value Per Share
-1.58
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
266.96M
Operating Revenue Per Share
1.82
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 13:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.